Analysis of data from several phase I and II clinical trials of a new cancer vaccine has shown it is capable of eliciting an immune response in most patients with bowel, kidney and prostate cancer, and that it may provide clinical benefit.
Analysis of data from several phase I and II clinical trials of a new cancer vaccine has shown it is capable of eliciting an immune response in most patients with bowel, kidney and prostate cancer, and that it may provide clinical benefit.